Article
Current Management of Patients with RPE65 Mutation-Associated Inherited Retinal Degenerations in Europe: Results of a Multinational Survey by the European Vision Institute Clinical Research Network.
Ophthalmic research - 1 Jan 2021
Lorenz Birgit, Tavares Joana, van den Born L Ingeborgh, Marques João P, Scholl Hendrik P N
Abstract excerpt
PURPOSE: The first ocular gene augmentation therapy, voretigene neparvovec (VN) (Luxturna®), has been approved for clinical use in an increasing number of countries (FDA USA 2017, EMA Europe 2018, MoHAP United Arab Emirates 2019, SFDA Saudi Arabia 2019, Swiss Medic Switzerland 2020, TGA Australia 2020, BFR Brazil 2020). Among the EVICR.net clinical centers, we conducted the first multinational survey to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.